JD.com (JD)
(Delayed Data from NSDQ)
$35.00 USD
+1.65 (4.95%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $34.95 -0.05 (-0.14%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Price, Consensus and EPS Surprise
JD 35.00 +1.65(4.95%)
Will JD be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for JD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for JD
October PPI In Line With Expectations
Wholesale Inflation Higher, Disney Posts Earnings Beat
JD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Alibaba's Q2 Earnings Coming Up: Should You Buy or Hold the Stock?
Top Stock Picks for Week of November 11, 2024
JD.com's Pre-Q3 Earnings Analysis: Should You Buy or Hold the Stock?
Other News for JD
David Tepper's Appaloosa exits Boeing & UPS, cuts Meta & Microsoft among top Q3 moves
Alibaba's Q2 Earnings Reflect Challenges Amidst China's Economic Slowdown
Soros boosts stake in AstraZeneca, exits Apple position
Soros boosts stake in AstraZeneca, exits Apple position
Alibaba's Fiscal Q2 2025 Earnings Underpin 3 Impending Catalysts